

Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2023

Organism Name	Antibiotics in common use (1st line reporting)										Vancomycin #	Reserved	Topical
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole		Ciprofloxacin #	Chloramphenicol
<i>S. aureus</i> (not MRSA)	561		19	100 ^a	91	92	99			100		97	97
MRSA *	27		0	0	85	89	89			100			
<i>S. saprophyticus</i> *	29	97		97				100	100	100			
<i>Enterococcus faecalis/spp</i> ^b	60	95						98			100		
<i>Streptococcus pneumoniae</i> *	17	100			82	88				86			
<i>Enterococcus faecium</i>	4												
<i>Streptococcus GrpA</i>	7												

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2023

Organism Name	Antibiotics in common use (1st line reporting)										Reserved (2nd line reporting)			
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin ^d	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole	Tetracycline	Ceftriaxone	Ciprofloxacin #	Meropenem #	Piperacillin-Tazobactam ^s
<i>Escherichia coli</i>	717	67	73		97	97	99	85	87		99	94	100	98
ESCM group	73	0	0		0	100		95	99		92	96	100	92
<i>Klebsiella oxytoca</i>	38	0	89		97	100		97	100		97	100	100	95
<i>Klebsiella pneumoniae</i>	46	0	83		93	100		86	91		100	96	100	96
<i>Proteus mirabilis</i>	46	91	98		98	96		88	93		100	94	100	100
<i>Haemophilus influenzae</i>	43	72	88	79					80	100				

West Coast

<i>Pseudomonas aeruginosa</i>	49
ESCM group: <i>Enterobacter spp</i>, <i>Serratia marcescens</i>, <i>Citrobacter spp</i>, <i>Morganella morganii</i>	

78	91	100
----	----	-----

* Tested on 10- 30 isolates

^a *S. aureus* susceptible to methicillin/flucloxacillin denotes susceptibility to cefazolin and amoxicillin-clavulanate

^b Enterococcus species are intrinsically resistant to cephalosporins

^c Includes Intermediate (Susceptible, Increased Exposure) results

^d Treatment of uncomplicated urinary tract infections only

Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

No data or not tested
Colour Interpretation
≥ 90% Susceptible
70 - 89% Susceptible
< 70% Susceptible